intravenous (some studies) Protocol: Cyclic -- 5-10 mg/day for 10-20 consecutive days, repeated every 4-6 months (2-3 cycles per year) Rationale: Brief telomerase activation extends telomeres, which then provide sustained replicative capacity during drug-free intervals Requirements: Sterile reconstitution, cold chain storage, injection supplies, injection technique Regulatory status: FDA Category 2 since 2024 (banned from compounding in the US) NAD+# Route: Oral (NMN, NR supplements)
Compared to other peptides studied for anti-aging effects, Epithalon occupies a unique position due to its specific focus on telomerase activation
Here, we determine structures of cagrilintide bound to Gs-coupled, active, amylin receptors (AMY 1 R, AMY 2 R, AMY 3 R) and calcitonin receptor (CTR) and compare cagrilintide interactions and the dynamics of receptor complexes with previously reported structures of receptors bound to rat amylin, salmon calcitonin or recently developed amylin-based peptides
Every patient who comes to me asking about BPC-157 gets a full evaluation medical history, labs, current medications, and a clear conversation about what we know, what we dont, and what the risk-benefit math looks like for them specifically
Insert the nozzle into the open nostril about half an inch or as far as it feels comfortable and tilt your head slightly forward while nozzle insertion
